159 related articles for article (PubMed ID: 6752630)
1. [Pharmacology and mechanism of action of etofibrate].
Schatton W
Med Welt; 1982 Sep; 33(38):1310-4. PubMed ID: 6752630
[No Abstract] [Full Text] [Related]
2. [Study of the antilipemic effect of etofibrate (Lipo-Merz)].
Słowińska R; Bochenek W; Unlot J
Pol Tyg Lek; 1983 Apr; 38(17):529-32. PubMed ID: 6356087
[No Abstract] [Full Text] [Related]
3. [Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
Schatton W; Holm E
Fortschr Med; 1986 Apr; 104(13):280-2. PubMed ID: 3699655
[No Abstract] [Full Text] [Related]
4. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
Machalke K; Djaja S; Richter E
Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613
[No Abstract] [Full Text] [Related]
5. [What is important in therapy of hyperlipoproteinemia. Lipo-Merz retard (etofibrate) lowers the atherogenic index].
Fortschr Med; 1982 Sep; 100(35):1622-3. PubMed ID: 7173769
[No Abstract] [Full Text] [Related]
6. [Lowering lipids rapidly and permanently with etofibrate].
von Bock und Polach U
Med Klin; 1982 Jan; 77(3):35-8. PubMed ID: 7057729
[No Abstract] [Full Text] [Related]
7. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
Altomonte L; Mingrone G; Negrini A; De Cunto F; Greco AV
Clin Ter; 1981 Jan; 96(1):31-8. PubMed ID: 7016409
[No Abstract] [Full Text] [Related]
8. [Lipid therapy with etofibrate. Reduction of multiple risk factors with an active substance. Report of an international seminar. 8-11 November 1989, Houston, Texas].
Fortschr Med Suppl; 1990; 85():1-15. PubMed ID: 2338325
[No Abstract] [Full Text] [Related]
9. [Therapeutic effects of bezafibrate in hyperlipidemia].
Kunesová M; Honková M; Zeman M; Mares P; Skorepa J
Cas Lek Cesk; 1983 May; 122(20):628-31. PubMed ID: 6342789
[No Abstract] [Full Text] [Related]
10. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
[TBL] [Abstract][Full Text] [Related]
11. [Longterm therapy and etofibrate (author's transl)].
Kaffarnik H; Schneider J; Schubotz R; Zöfel P
MMW Munch Med Wochenschr; 1980 Jan; 122(3):95-8. PubMed ID: 6767931
[TBL] [Abstract][Full Text] [Related]
12. [Comparative research on etofibrate retard and fenofibrate in hyperlipoproteinemia].
Schwartzkopff W; Schilling A
Med Welt; 1980 Dec; 31(50):1845-50. PubMed ID: 7464535
[No Abstract] [Full Text] [Related]
13. [Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
Janka HU; Standl A; Holler HD; Mehnert H
MMW Munch Med Wochenschr; 1982 May; 124(21):535-7. PubMed ID: 6810123
[No Abstract] [Full Text] [Related]
14. [Atherosclerosis treatment with etofibrate retard. New perspectives].
Degenring FH; Schatton W; Hotz W
Fortschr Med; 1983 Aug; 101(30):1391-6. PubMed ID: 6618402
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K
Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826
[No Abstract] [Full Text] [Related]
16. Bioavailability studies of etofibrate in rhesus monkeys.
Waller AR; Chasseaud LF; Taylor T; Schatton W
Arzneimittelforschung; 1985; 35(2):489-92. PubMed ID: 4039571
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
Bruneder H; Klein HJ
Dtsch Med Wochenschr; 1981 Dec; 106(49):1653-6. PubMed ID: 7308007
[TBL] [Abstract][Full Text] [Related]
18. [Plafibride--is it an effective drug as a hypolipemic agent?].
Joven J
Med Clin (Barc); 1985 Apr; 84(15):632. PubMed ID: 3999857
[No Abstract] [Full Text] [Related]
19. The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans.
Horváth M; Varsányl M; Jovanovich N; Romics L; Gerö S
Allergol Immunopathol (Madr); 1990; 18(2):95-9. PubMed ID: 2371944
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials of plafibride in geriatric patients.
Demichelis Genesio MA; Bracons R; Vicens B; Zapatero J; Bruseghini L
Arzneimittelforschung; 1981; 31(10a):1852-5. PubMed ID: 7198465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
